scholarly journals Available COVID-19 vaccine platforms: A roadmap to eclipsing the SARS-CoV-2 viral saga

10.3823/853 ◽  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nancy El Beayni ◽  
George Araj ◽  
Abdul Rahman Bizri ◽  
Najwa Khuri ◽  
Asem Shehabi
Keyword(s):  
Clinical Trials ◽  
Mechanism Of Action ◽  
Medical Community ◽  
Vaccine Production ◽  
Advanced Stages ◽  
Emerging Virus

The coronavirus disease 2019 (COVID-19) have devastated the globe and continues to be a protracted saga. In the absence of specific efficacious medical remedies, efforts to encounter and contain this emerging virus concentrated on vaccine production. A plethora of novel vaccines has been under development by major companies in different countries. To date, around 60 vaccines are in clinical trials with many other ones continuously added to the evolving pipeline. The variety in their corresponding designed platform and phases, warrants to tackle and understand what is being presented in the literature and launched in the market.  Thus, this study is intended to enlighten and educate the medical community by reviewing the different vaccine platforms, and briefly explaining their mechanism of action with an emphasis on those that reached most advanced stages.

scholarly journals Gomeopatiya i allergiya. Professional'nye debaty v zerkale dokazatel'noy meditsiny

2017 ◽  
Vol 14 (1) ◽  
pp. 16-23
Author(s):  
N G Astafieva ◽  
D Y Kobzev
Keyword(s):  
Clinical Trials ◽  
Mechanism Of Action ◽  
Comparative Studies ◽  
Analytical Methods ◽  
Scientific Evidence ◽  
Medical Science ◽  
Point Of View ◽  
Medical Community ◽  
Cochrane Reviews ◽  
Modern Analytical

At the present time there is no credible scientific evidence on the effectiveness of homeopathy in asthma, allergies and other diseases. In the available publications, Cochrane reviews, meta-analyzes of homeopathy effect comparable to placebo. From a scientific point of view, we did not receive an explanation mechanism of action of homeopathic dilutions of drugs, laid down in the concept of potentiation. In the light of the best available data to date there is no reason to include homeopathy in clinical guidelines for the treatment of patients with various diseases. To change the view of the value of homeopathic medicines need modern analytical methods, revealing the structure of the proposed pills and other medicines, and to study the true therapeutic homeopathy capabilities required to conduct comparative studies, clinical trials, appropriate medical science and made according to strict rules, adopted by the international medical community.

scholarly journals Redundant trials can be prevented, if the EU clinical trial regulation is applied duly

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Daria Kim ◽  
Joerg Hasford
Keyword(s):  
Clinical Trials ◽  
Health Risks ◽  
Ethics Committees ◽  
Medical Community ◽  
Significant Extent ◽  
Regulatory Requirements ◽  
Trial Participants ◽  
Clinical Trials Regulation ◽  
Clinical Trial Regulation ◽  
The Eu

Abstract The problem of wasteful clinical trials has been debated relentlessly in the medical community. To a significant extent, it is attributed to redundant trials – studies that are carried out to address questions, which can be answered satisfactorily on the basis of existing knowledge and accessible evidence from prior research. This article presents the first evaluation of the potential of the EU Clinical Trials Regulation 536/2014, which entered into force in 2014 but is expected to become applicable at the end of 2021, to prevent such trials. Having reviewed provisions related to the trial authorisation, we propose how certain regulatory requirements for the assessment of trial applications can and should be interpreted and applied by national research ethics committees and other relevant authorities in order to avoid redundant trials and, most importantly, preclude the unnecessary recruitment of trial participants and their unjustified exposure to health risks.

Mechanism of action and clinical trials of Mpl ligand

1997 ◽  
Vol 4 (5) ◽  
pp. 312-316 ◽  
Author(s):  
William P. Sheridan ◽  
David J. Kuter
Keyword(s):  
Clinical Trials ◽  
Mechanism Of Action

scholarly journals Target Therapy in Acute Myeloid Leukemia

2020 ◽  
Author(s):  
Vasko Graklanov
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Acute Leukemia ◽  
Mechanism Of Action ◽  
Myeloid Leukemia ◽  
Target Therapy ◽  
New Drugs ◽  
Cytotoxic Treatment ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is the most common form of acute leukemia in elderly patients. Over the past four decades the basic therapeutic armamentarium was the standard cytotoxic treatment. The new insights in understanding the pathogenesis of AML was the momentum that revolutionized the treatment landscape in AML. The last five years unprecedented growth has been seen in the number of target therapy drugs for the treatment of AML. These new drugs did not just have a clinical benefit as single agents but also have improved AML patient outcomes if combined with conventional cytotoxic therapy. Here, we review recent advances in target-based therapy for patients with AML focusing on their mechanism of action and the results from already published clinical trials.

scholarly journals Current approaches to the management of diabetic retinopathy

2014 ◽  
Vol 17 (3) ◽  
pp. 122-128 ◽  
Author(s):  
Tatiana Yul'evna Demidova ◽  
Yulia Alexandrovna Trakhtenberg
Keyword(s):  
Risk Factors ◽  
Clinical Trials ◽  
Diabetic Retinopathy ◽  
Mechanism Of Action ◽  
Treatment Options ◽  
Current Status ◽  
Antiangiogenic Agents

This review reflects the current status of the diabetic retinopathy treatment problem and describes the results of the largest trials on epidemiology, screening and the risk factors for complications. In addition, this article describes the current approaches and treatment options for diabetic retinopathy, including a description of fenofibroic acid with its mechanism of action and data from clinical trials. This article also contains information on antiangiogenic agents for intravitreal administration.

Zastosowanie kwasu azelainowego w wybranych schorzeniach dermatologicznych

2018 ◽  
Vol 21 (4) ◽  
Author(s):  
Paula Dębek ◽  
Anna Piotrowska ◽  
Magdalena Nastałek ◽  
Natalia Totko-Borkusiewicz ◽  
Olga Czerwińska-Ledwig ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Mechanism Of Action ◽  
Azelaic Acid ◽  
Acid Treatment ◽  
Wide Spectrum ◽  
Acne Vulgaris ◽  
Acne Rosacea

Introduction. Dermatoses, such as acne vulgaris, acne rosacea and hyperpigmentations, are an increasingly common problem, their chronic character affecting the quality of life of the affected people. One of the substances with a multidirectional mechanism of action and a wide spectrum of applications is azelaic acid. Aim. The aim of this paper was to present azelaic acid as a substance suitable for treatment of many skin problems. Material and methods. The authors have analyzed the literature from 1986-2018, looking for works indicating the mechanism, effectiveness and safety of azelaic acid treatment in selected diseases. Results. This ingredient proved to meet the high requirements. Conclusions. Systematic use of azelaic acid reduces acne lesions, lightens discolorations and eliminates most of the symptoms of rosacea. It is used alone or in polytherapy, however combined therapies require further clinical trials indicating the directionality of such treatment.

scholarly journals Organoids: life in three dimensions- a review

2019 ◽  
Vol 7 (1) ◽  
pp. 5
Author(s):  
Akhila CNV ◽  
Ravi Prakash A ◽  
Rajini Kanth M ◽  
Sreenath G ◽  
Sowmya K ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Drug Testing ◽  
Molecular Level ◽  
Imaging Techniques ◽  
Three Dimensions ◽  
Vaccine Production ◽  
Research Fields ◽  
Complex Interactions ◽  
Open The Doors ◽  
Dimensional Cell

Most of the diseases in humans are as a result of complex interactions occurring at cellular and molecular level. Research today has been focused in an attempt to reveal precisely the cellular evolution into pathogenesis. There are vast array of research fields, which include molecular biology, imaging techniques, etc. One of such field recently advancing worldwide is “Organotyping”. It is the successor of two dimensional cell cultures. Miniature organs and disease models can be produced from cells having the ability to proliferate and differentiate, by adopting definite protocols. Organoids are the potential tools to probe human biology and diseases; thereby they may change the approach to study diseases and provide treatment, in a more beneficiary way to the patient. Also organoids are used in vaccine production, cancer research, microbiology, tissue regeneration, drug testing, etc. Clinical trials are more devastating and may cost life of patients included in study. As such, organoids can be included in the protocols of clinical trials, through which the outcome of the study can be estimated. They open the doors for newer research methods and innovations, which are in peak requirement of present day scenario where new diseases are emerging and the diseases already existing are not yet cured.   

scholarly journals Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy

2020 ◽  
Vol 21 (8) ◽  
pp. 2793 ◽  
Author(s):  
Zhaoying Fu ◽  
Jim Xiang
Keyword(s):  
Monoclonal Antibody ◽  
Clinical Trials ◽  
Cancer Therapy ◽  
Specific Binding ◽  
High Specificity ◽  
Medical Community ◽  
Therapeutic Uses ◽  
Repeated Use ◽  
Systematic Evolution ◽  
Exponential Enrichment

The arrival of the monoclonal antibody (mAb) technology in the 1970s brought with it the hope of conquering cancers to the medical community. However, mAbs, on the whole, did not achieve the expected wonder in cancer therapy although they do have demonstrated successfulness in the treatment of a few types of cancers. In 1990, another technology of making biomolecules capable of specific binding appeared. This technique, systematic evolution of ligands by exponential enrichment (SELEX), can make aptamers, single-stranded DNAs or RNAs that bind targets with high specificity and affinity. Aptamers have some advantages over mAbs in therapeutic uses particularly because they have little or no immunogenicity, which means the feasibility of repeated use and fewer side effects. In this review, the general properties of the aptamer, the advantages and limitations of aptamers, the principle and procedure of aptamer production with SELEX, particularly the undergoing studies in aptamers for cancer therapy, and selected anticancer aptamers that have entered clinical trials or are under active investigations are summarized.

scholarly journals Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches

2019 ◽  
Vol 20 (7) ◽  
pp. 1616 ◽  
Author(s):  
Wenbo Li ◽  
Zheng Sun
Keyword(s):  
Clinical Trials ◽  
Enzymatic Activity ◽  
Histone Deacetylase ◽  
Mechanism Of Action ◽  
Histone Deacetylase Inhibitors ◽  
Catalytic Domain ◽  
Hdac Inhibitors ◽  
Mechanistic Studies ◽  
Low Toxicity ◽  
Strict Specificity

Histone deacetylase inhibitors (HDIs) are a class of prominent epigenetic drugs that are currently being tested in hundreds of clinical trials against a variety of diseases. A few compounds have already been approved for treating lymphoma or myeloma. HDIs bind to the zinc-containing catalytic domain of the histone deacetylase (HDACs) and they repress the deacetylase enzymatic activity. The broad therapeutic effect of HDIs with seemingly low toxicity is somewhat puzzling when considering that most HDIs lack strict specificity toward any individual HDAC and, even if they do, each individual HDAC has diverse functions under different physiology scenarios. Here, we review recent mechanistic studies using omics approaches, including epigenomics, transcriptomics, proteomics, metabolomics, and chemoproteomics, methods. These omics studies provide non-biased insights into the mechanism of action for HDIs.

Sign in / Sign up

Export Citation Format

Share Document